![](https://endpts.com/wp-content/uploads/2020/10/News_briefing_FE.jpg)
Takeda signs option deal for TKI inhibitor; Enveda's $55M raise
Plus, news about IN8bio, Rezolute, BeiGene and NewBridge:
Takeda, Ascentage ink option deal: The deal involves a compound called olverembatinib, which Takeda
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.